Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Mala Chakraborty"'
Autor:
David S.J. Allan, Chuanfeng Wu, Ryland D. Mortlock, Mala Chakraborty, Katayoun Rezvani, Jan K. Davidson-Moncada, Cynthia E. Dunbar, Richard W. Childs
Publikováno v:
Molecular Therapy: Oncolytics, Vol 28, Iss , Pp 74-87 (2023)
Multiple clinical trials exploring the potential of adoptive natural killer (NK) cell therapy for cancer have employed ex vivo expansion using feeder cells to obtain large numbers of NK cells. We have previously utilized the rhesus macaque model to c
Externí odkaz:
https://doaj.org/article/1edf27f82c9247a59d26f5b1e82ee10b
Autor:
David S.J. Allan, Mala Chakraborty, Giacomo C. Waller, Michael J. Hochman, Akkapon Poolcharoen, Robert N. Reger, Richard W. Childs
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss , Pp 559-571 (2021)
Transduction of primary human natural killer (NK) cells with lentiviral vectors has historically been challenging. We sought to evaluate multiple parameters to optimize lentiviral transduction of human peripheral blood NK cells being expanded to larg
Externí odkaz:
https://doaj.org/article/2d3b060a8c104e1cbf96970d0c3841f6
Autor:
Long Chen, Richard Childs, Robert Reger, Mala Chakraborty, Joseph Andrew Clara, Emily R Levy, Stefan Barisic, Elena Cherkasova, David S J Allan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/81f4ca06542045a8b7b5a461ddb90ebf
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/89bb6791d65f4caa80bbcc6664b4340b
Autor:
Gustaf Wigerblad, Seth A. Warner, Marcos J. Ramos-Benitez, Lela Kardava, Xin Tian, Rui Miao, Robert Reger, Mala Chakraborty, Susan Wong, Yogendra Kanthi, Anthony F. Suffredini, Stefania Dell’Orso, Stephen Brooks, Christopher King, Oksana Shlobin, Steven D. Nathan, Jonathan Cohen, Susan Moir, Richard W. Childs, Mariana J. Kaplan, Daniel S. Chertow, Jeffrey R. Strich
Publikováno v:
Science advances, vol 9, iss 1
Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase 2 placebo-controlled randomi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b029f0b5bfbeacbd65b2880c83798186
https://pubmed.ncbi.nlm.nih.gov/36598976
https://pubmed.ncbi.nlm.nih.gov/36598976
Autor:
Richard W. Childs, Giacomo C. Waller, Mala Chakraborty, Michael J. Hochman, David S.J. Allan, Akkapon Poolcharoen, Robert Reger
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss, Pp 559-571 (2021)
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss, Pp 559-571 (2021)
Transduction of primary human natural killer (NK) cells with lentiviral vectors has historically been challenging. We sought to evaluate multiple parameters to optimize lentiviral transduction of human peripheral blood NK cells being expanded to larg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff35873bc83eef72dcea3ec08df48f2
https://doi.org/10.1016/j.omtm.2021.01.008
https://doi.org/10.1016/j.omtm.2021.01.008
Autor:
Long Chen, Elena Cherkasova, Stephanie Pierre, Savannah England, Muna Igboko, Joseph Clara, Stefan Barisic, Angie Parrizzi, Rosa Rios Nadal, David Allan, Mala Chakraborty, Robert Reger, Richard Childs
Publikováno v:
Cancer Research. 83:5210-5210
Human endogenous retroviruses (HERVs) comprise 8% of the human genome and can be abnormally expressed in different tumor cells. Our lab discovered a unique and highly immunogenic HERV-E, CT-RCC HERV-E, that is selectively expressed in most clear cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e6419775a75d7351aa2d26ebaef2f793
https://doi.org/10.1158/1538-7445.am2023-5210
https://doi.org/10.1158/1538-7445.am2023-5210
Autor:
Joseph Andrew Clara, Emily R Levy, Robert Reger, Stefan Barisic, Long Chen, Elena Cherkasova, Mala Chakraborty, David S J Allan, Richard Childs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundAdoptive transfer of natural killer (NK) cells with augmented antibody-dependent cellular cytotoxicity (ADCC) capabilities and resistance to CD38 targeting has the potential to enhance the clinical anti-myeloma activity of daratumumab (DARA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84998a06d9c066485582ef85bff615bb
https://pubmed.ncbi.nlm.nih.gov/35135865
https://pubmed.ncbi.nlm.nih.gov/35135865
Autor:
Mala Chakraborty, Richard W. Childs, Emily R Levy, David S.J. Allan, Joseph A. Clara, Robert Reger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundNatural killer (NK) cells play an important role in the antitumor responses of therapeutic monoclonal antibodies (mAbs) by mediating antibody-dependent cellular cytotoxicity (ADCC). ADCC occurs when tumor-ligated mAbs trigger NK cell killin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ba6d6b5bb97e0e0640c1579f563b80
https://doaj.org/article/89bb6791d65f4caa80bbcc6664b4340b
https://doaj.org/article/89bb6791d65f4caa80bbcc6664b4340b
Autor:
Jeffrey R Strich, Jonathan Cohen, Marcos J Ramos-Benitez, Richard T. Davey, Mala Chakraborty, Janet Valdez, Vikramjit Khangoora, Josef Rivero, Julie Erb-Alvarez, Susan Wong, Jungnam Joo, Shambhu Aryal, Anthony F. Suffredini, Robert Reger, Jennifer Jo Kyte, Richard W Childs, Kareem Ahmad, Daniel S. Chertow, Georg Aue, Ick-Ko Kim, Kenneth N. Olivier, Steven D. Nathan, Mohamed Samour, Ruba Shalhoub, Seth Warner, Benjamin Colton, A. Whitney Brown, Edwinia Battle, Rebecca Hays, Xin Tian, Christopher S. King, Yazan Migdady, Oksana A. Shlobin, A. Claire Collins
Publikováno v:
Clin Infect Dis
Background Coronavirus disease 2019 (COVID-19) requiring hospitalization is characterized by robust antibody production, dysregulated immune response, and immunothrombosis. Fostamatinib is a novel spleen tyrosine kinase inhibitor that we hypothesize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3264ae39a7f0f3692609e215d280e3c4
https://pubmed.ncbi.nlm.nih.gov/34467402
https://pubmed.ncbi.nlm.nih.gov/34467402